HSC gene therapy is successfully being used in clinics to treat non-cancerous brain disorders, and a preclinical GBM mouse model based on TGF-β-blocking HSC gene therapy in combination with irradiation has been shown to reduce tumor burden and significantly prolong survival compared with monotherapies and control groups [149]. The gene discussed is TGFB1; the disease is neoplasm.